



NDA 22-058/S-001

Indevus Pharmaceuticals, Inc.
Attention: John Berryman
Vice President, Regulatory Affairs
33 Hayden Avenue
Lexington, MA 02421

Dear Mr. Berryman:

Please refer to your supplemental new drug application dated May 18, 2007, received May 23, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Supprelin LA (histrelin acetate) subcutaneous implant, 50 mg.

This "Changes Being Effected" supplemental new drug application provides for a change in the listed device for this drug, including modifications to the device (insertion tool) pouch label.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (insertion tool pouch label) submitted May 18, 2007.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 22-058/S-001.**" Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Metabolism and Endocrinology Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jennifer Johnson, Regulatory Project Manager, at (301) 796-2194.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Device (Insertion Tool) Pouch Label

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Eric Colman
11/21/2007 04:02:21 PM
Eric Colman for Mary Parks